Hybridan

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Your Partner for Growth

Your Partner for Growth, Hybridan

Equity Bottom-Up

<ul>
<li>The developer, manufacturer, and regulatory services provider for rapid diagnostic tests and med-tech reports for FY June 2025.</li>
<li>Revenue increased 40% to £8.6m, which included a grant and contribution from the acquired CS Lifesciences.</li>
<li>The EBITDA loss increased to £3.5m from a loss of £1.4m. Operational highlights include a $2m US contract win for the development of STD tests running 2026. </li>
</ul>


The developer, manufacturer, and regulatory services provider for rapid diagnostic tests and med-tech reports for FY June 2025.
Revenue increased 40% to £8.6m, which included a grant and contribution from the acquired CS Lifesciences.
The EBITDA loss increased to £3.5m from a loss of £1.4m. Operational highlights include a $2m US contract win for the development of STD tests running 2026. 


Hybridan Small Cap Feast: 11 November 2025

Abingdon Health

Hybridan Small Cap Feast: 11 November 2025